Arnold Lesley M
Division of Women's Health Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
J Clin Psychiatry. 2008;69 Suppl 2:14-9.
According to the American College of Rheumatology, fibromyalgia is widespread pain of at least 3 months' duration in combination with pain at 11 or more of 18 specific tender point sites on the body. Many individuals with fibromyalgia also have comorbid psychiatric disorders, which can present diagnostic dilemmas and require additional treatment considerations to optimize patient outcomes. Fibromyalgia has been found to be strongly associated with depressive and anxiety symptoms, a personal or family history of depression, and accompanying antidepressant treatment. Psychiatric comorbidities negatively impact the severity and course of fibromyalgia. Pharmacotherapy can be employed to control fibromyalgia and comorbid mood and anxiety disorders. Additionally, nonpharmacologic therapies for fibromyalgia and comorbid psychiatric disorders include cognitive-behavioral therapy and aerobic exercise. The efficacy of pharmacologic and nonpharmacologic treatments is examined in this article, as well as the diagnostic difficulties that comorbid disorders present.
根据美国风湿病学会的定义,纤维肌痛是一种持续至少3个月的广泛性疼痛,并伴有身体18个特定压痛点部位中11个或更多部位的疼痛。许多纤维肌痛患者还伴有精神疾病,这可能会带来诊断难题,并需要额外的治疗考虑以优化患者的治疗效果。研究发现,纤维肌痛与抑郁和焦虑症状、个人或家族抑郁病史以及伴随的抗抑郁治疗密切相关。精神疾病共病会对纤维肌痛的严重程度和病程产生负面影响。药物治疗可用于控制纤维肌痛以及共病的情绪和焦虑障碍。此外,针对纤维肌痛和共病精神疾病的非药物治疗包括认知行为疗法和有氧运动。本文探讨了药物治疗和非药物治疗的疗效,以及共病疾病带来的诊断困难。